Eisai Says Lenvatinib Lost in UK Market Access Maze Due To NICE Inaction
Executive Summary
Japan's Eisai is considering all options including legal action and reducing its investment in the UK to force NICE to make its potential blockbuster TKI cancer drug lenvatinib available sooner to patients with advanced thyroid cancer via the publicly-funded National Health Service.
You may also be interested in...
Speedy NICE Support For Eisai's Lenvima In Liver Cancer
It took NICE nearly three years to offer routine access to Lenvima for thyroid cancer but it has taken just three months from European approval to recommend the drug for advanced or unresectable hepatocellular carcinoma.
Japan Issues Strong Warning Over Brexit
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
UK Cancer Drugs Fund Reforms Get Cautious Welcome, But More Needed
NHS England has issued new guidelines on how cancer drugs will be appraised and funded in the UK, including the operation of the controversial Cancer Drugs Fund (CDF), which is being replaced by a new fund controlled by the HTA NICE from the end of July this year.